I. Alex Bowman, MD

🤔 Can the bladder be spared? Comparing survival outcomes after surgery vs radical radiotherapy for cN+ #BladderCancer ➡️ brnw.ch/21wC3Jq #blcsm #radonc #surgonc @swinton_martin @achoud72

Interested in joining a great team in a great location? We’re looking to add another GU medical oncologist to our growing multidisciplinary program in the Phoenix metro area. Medical Oncologist with Genitourinary Focus doximity.com/careers/job_ca…

Hope you’ll join me for a monthly, #MensHealth educational group for men in our Arizona #community. I’ll be hosting this amazing #breakfast club free for all men; especially those men who are impacted by #cancer. We meet the third Saturday of each month, 10am - 12noon.

I'll be presenting on PSMA imaging and Therapy at the Society for Nuclear Medicine and Molecular Imaging Symposia in Phoenix 11/3/22. Registration is open and free. snmmi.org/psmaphoenix

Had the privilege of addressing the Arizona ACS CAN summit on the topic of ctDNA as a cancer biomarker. Very much appreciate their work to enshrine insurance coverage for biomarker testing in AZ law.

A little double rainbow action as a palate-cleanser for this week.

As amazing as the results are in the recently reported dostarlimab trial in dMMR CRC, the press must do a better job highlighting it as a triumph of precision medicine/patient selection, rather than drug development.

Thanks again to @SunHealthAZ for giving me the opportunity to talk to a great group of folks about the basics of prostate cancer. Coffee with Gina and Friends: Prostate Cancer Facts Every Man & Woman S... youtu.be/sCUfuvKWbYI via @YouTube.

Don't miss #GU22 poster presentation from newest @KCPUTSW leadership team member Scott Schwartzman, M.D., on active surveillance and role of genomic markers associated with #kidneycancer aggressiveness in guiding patient selection. @ASCO @OncoAlert @urotoday @utswcancer

Tune in to #GU22 Best of Journals presentation by @PayalKapur5 highlighting recent advances in renal tumor classification as well as two promising biomarker studies. @ASCO @OncoAlert @UroToday @utswcancer @UTSW_Pathology

@AzadOncology @NimaSharifiMD @DrMHofman @scserendipity1 We get a little more consolidation within pharma and this might actually be feasible.

DIALUP study? D - Docetaxel I - Ipi + Nivo A - AKT inhibitor Lu - Lu-PSMA P - PARP inhibitor #ProstateCancer won't know what hit it! @NimaSharifiMD @DrMHofman @scserendipity1

Introducing my daughter to academics as we work on her kindergarten presentation: D: We can just steal ideas from this book. Me: That’s called research.

Rare histology in #UrothelialCarcinoma #GU22. Our poster on neoadjuvant chemotherapy in ~200 patient with small cell histology. We explore different chemotherapy regimens including ifosfamide, etoposide, gem/cis, MVAC and others. 1/n

As nice as it would have been to attend #GU22 in person, the company for the virtual conference isn’t bad.

Well, my Super Bowl plans for the kids are going great, how about you?

@ChapinMD stern, then cloud or aioli

Do you all start Wordle with the same word every day? Mine is Adieu.